Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2008 Nov 18;37(3):167–172. [Article in Spanish] doi: 10.1157/13085351

Actitud ante una mujer posmenopáusica que consulta por sofocos y dispareunia

D Sánchez-Mariscal a,⁎, E Bailón-Muñoz b
PMCID: PMC7668917  PMID: 16527139

The content is available as a PDF (112.3 KB).

Bibliografía

  • 1.Kronenberg F., Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med. 2002;137:805–813. doi: 10.7326/0003-4819-137-10-200211190-00009. [DOI] [PubMed] [Google Scholar]
  • 2.Albertazzi P., Purdie D. The nature and utility of the phytoestrogens: a review of the evidence. Maturitas. 2002;42:173–185. doi: 10.1016/s0378-5122(02)00024-5. [DOI] [PubMed] [Google Scholar]
  • 3.Sommer B., Avis N., Meyer P., Ory M., Madden T., Kagawa-Singer M. Attitudes toward menopause and aging across ethnic/racial groups. Psychosom Med. 1999;61:868–875. doi: 10.1097/00006842-199911000-00023. [DOI] [PubMed] [Google Scholar]
  • 4.Avis N.E., Stellato R., Crawford S., Bromberger J., Ganz P., Cain V. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med. 2001;52:345–356. doi: 10.1016/s0277-9536(00)00147-7. [DOI] [PubMed] [Google Scholar]
  • 5.Lock M. Symptom reporting at menopause: a review of crosscultural findings. Br Menopause Soc. 2002;8:132–136. doi: 10.1258/136218002100321965. [DOI] [PubMed] [Google Scholar]
  • 6.De la Gándara J., Sánchez J., Díez M.A., Monje E. Influencia de las actitudes, expectativas y creencias en la adaptación a la menopausia. An Psiquiatr. 2003;8:329–336. [Google Scholar]
  • 7.Utian W.H., Boggs P.P. The North American Menopause Society 1998, Menopause Survey. Part I: postmenopausal women's perceptions about menopause and midlife. Menopause. 1999;6:122–128. [PubMed] [Google Scholar]
  • 8.Delgado A., Sánchez M.C., Galindo I., Pérez C., Duque M.J. Women's attitudes to menopause and predictive variables. Aten Primaria. 2001;27:3–11. doi: 10.1016/S0212-6567(01)78765-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Instituto Vasco de la Mujer; Vitoria-Gasteiz: 1993. Mujeres y Salud en la Comunidad Autónoma de Euskadi. [Google Scholar]
  • 10.La menopausia en la Comunidad de Madrid. Aspectos socio-sanitarios. Madrid: Consejería de Sanidad y Asuntos Sociales. Comunidad de Madrid. Documentos Técnicos de Salud Pública; 1996.
  • 11.McKinlay S.M. The normal menopause transition: an overview. Maturitas. 1996;23:137–145. doi: 10.1016/0378-5122(95)00985-x. [DOI] [PubMed] [Google Scholar]
  • 12.Brown W.J., Mishra G.D., Dobson A. Changes in physical symptoms during the menopause transition. Int J Behav Med. 2002;9:53–67. doi: 10.1207/s15327558ijbm0901_04. [DOI] [PubMed] [Google Scholar]
  • 13.Avis N.E., Stellato R., Crawford S., Bromberger J., Ganz P., Cain V. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med. 2001;52:345–356. doi: 10.1016/s0277-9536(00)00147-7. [DOI] [PubMed] [Google Scholar]
  • 14.Dennerstein L., Dudley E.C., Hopper J.L., Guthrie J.R., Burger H.G. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96:351–358. doi: 10.1016/s0029-7844(00)00930-3. [DOI] [PubMed] [Google Scholar]
  • 15.MacLennan A., Lester S., Moore V. The Cochrane Library, Issue 1. John Wiley & Sons, Ltd.; Chichester: 2004. Oral oestrogen replacement therapy versus placebo for hot flushes (Cochrane Review) [DOI] [PubMed] [Google Scholar]
  • 16.Archer D.F. Percutaneous 17-beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Menopause. 2003;10:516–521. doi: 10.1097/01.GME.0000070526.74726.8A. [DOI] [PubMed] [Google Scholar]
  • 17.Rovati L.C., Setnikar I., Genazzani A.R. Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Italian Menopause Research Group. Gynecol Endocrinol. 2000;14:282–291. doi: 10.3109/09513590009167695. [DOI] [PubMed] [Google Scholar]
  • 18.Notelovitz M., Cassel D., Hille D., Furst K.W., Dain M.P., Vande-Pol C., Skarinsky D. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. Am J Obstet Gynecol. 2000;182:7–12. doi: 10.1016/s0002-9378(00)70483-2. [DOI] [PubMed] [Google Scholar]
  • 19.Meeuwsen I.B., Samson M.M., Duursma S.A., Verhaar H.J. The influence of tibolone on quality of life in postmenopausal women. Maturitas. 2002;41:35–43. doi: 10.1016/s0378-5122(01)00251-1. [DOI] [PubMed] [Google Scholar]
  • 20.Landgren M.B., Bennink H.J., Helmond F.A., Engelen S. Doseresponse analysis of effects of tibolone on climacteric symptoms. BJOG. 2002;109:1109–1114. doi: 10.1111/j.1471-0528.2002.02020.x. [DOI] [PubMed] [Google Scholar]
  • 21.Wesel S., Bosuma W.B. The alternative to hormonal treatment of menopausal vasomotor flushes: veralipride. Sem Hop. 1983;59:596–599. [PubMed] [Google Scholar]
  • 22.Schindler A.E., Heners D., Pater T., Wendel U., Donath E.M. The treatment of the climacteric syndrome with a combination of low- dose clonidine and low-dose conjugated estrogens. Fortschr Med. 1984;102:1213–1216. [PubMed] [Google Scholar]
  • 23.Hammond M.G., Hatley L., Talbert L.M. A double blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes. J Clin Endocrinol Metab. 1983;58:1158–1160. doi: 10.1210/jcem-58-6-1158. [DOI] [PubMed] [Google Scholar]
  • 24.Guttuso T., Jr, Kurlan R., McDermott M.P., Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003;101:337–345. doi: 10.1016/s0029-7844(02)02712-6. [DOI] [PubMed] [Google Scholar]
  • 25.Loprinzi C.L., Kugler J.W., Sloan J.A., Mailliard J.A., LaVasseur B.I., Barton D.L. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet. 2000;356:2059–2063. doi: 10.1016/S0140-6736(00)03403-6. [DOI] [PubMed] [Google Scholar]
  • 26.Stearns V., Beebe K L., Iyengar M., Dube E. Paroxetine controlled release in treatment of menopausal hot flashes. JAMA. 2003;289:2827–2834. doi: 10.1001/jama.289.21.2827. [DOI] [PubMed] [Google Scholar]
  • 27.Loprinzi C.L., Sloan J.A., Pérez E.A., Quella S.K., Stella P.J., Mailliard J.A. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002;20:1578–1583. doi: 10.1200/JCO.2002.20.6.1578. [DOI] [PubMed] [Google Scholar]
  • 28.Cardozo L., Bachmann G., McClish D., Fonda D., Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998;92:722–727. doi: 10.1016/s0029-7844(98)00175-6. [DOI] [PubMed] [Google Scholar]
  • 29.Suckling J., Lethaby A., Kennedy R. The Cochrane Library, Issue 4. John Wiley & Sons, Ltd; Chichester: 2003. Local estrogen for vaginal atrophy in postmenopausal women (Cochrane Methodology Review) [DOI] [PubMed] [Google Scholar]
  • 30.Bygdeman M., Swahn M.L. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23:259–263. doi: 10.1016/0378-5122(95)00955-8. [DOI] [PubMed] [Google Scholar]
  • 31.Dennerstein L., Guthrie J., Birkhäuser M., Sherman S. Symptoms and the menopause. International Position Paper on Women's Health and Menopause: a comprehensive Approach. National Institutes of Health. 2002:43–63. [Google Scholar]
  • 32.Kondo A., Kato K., Saito M., Otani T. Prevalence of handwashing incontinence in females in comparison with stress and urge incontinence. Neurourology & Urodynamics. 1990;9:330–331. [Google Scholar]
  • 33.Avis N.E., Crawford S., Stellato R., Longcope C. Longitudinal study of hormone levels and depression among women transitioning through menopause. Climacteric. 2001;4:243–249. [PubMed] [Google Scholar]
  • 34.Hardy R., Kuh D. Change in psychological and vasomotor symptom reporting during the menopause. Soc Sci Med. 2002;55:1975–1988. doi: 10.1016/s0277-9536(01)00326-4. [DOI] [PubMed] [Google Scholar]
  • 35.Meyer P.M., Powell L.H., Wilson R.S., Everson-Rose S.A., Kravitz H.M., Luborsky J.L. A population-based longitudinal study of cognitive functioning in the menopausal transition. Neurology. 2003;61:801–806. doi: 10.1212/01.wnl.0000079051.91602.e2. [DOI] [PubMed] [Google Scholar]
  • 36.Kondo A., Kato K., Saito M., Otani T. Prevalence of handwashing incontinence in females in comparison with stress and urge incontinence. Neurourology & Urodynamics. 1990;9:330–331. [Google Scholar]
  • 37.De Laet C.E., Pols H.A. Fractures in the elderly: epidemiology and demography. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:171–179. doi: 10.1053/beem.2000.0067. [DOI] [PubMed] [Google Scholar]
  • 38.Kanis J.A., Johnell O., De Laet C., Jonsson B., Oden A., Ogelsby A.K. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res. 2002;17:1237–1244. doi: 10.1359/jbmr.2002.17.7.1237. [DOI] [PubMed] [Google Scholar]
  • 39.Black D.M., Steinbuch M., Palermo L., Dargent-Molina P., Lindsay R., Hoseyni M.S. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int. 2001;12:519–528. doi: 10.1007/s001980170072. [DOI] [PubMed] [Google Scholar]
  • 40.The Swedish Council on Technology Assesment in Health Care Bone density measurement – A systematic revies. Report from SBU. The Swedish Council on Technology Assesment in Health Care. J Intern Med. 1997;241(Suppl 739):1–60. [PubMed] [Google Scholar]
  • 41.Group for th Women's Health Initiative Investigators Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Inititive Randomized Controlled Trial. JAMA. 2002;288:321–333. doi: 10.1001/jama.288.3.321. [DOI] [PubMed] [Google Scholar]
  • 42.Barrett-Connor E., Wehren L.E., Siris E.S., Miller P., Chen Y.T., Abbott T.A., 3rd Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA)study. Menopause. 2003;10:412–419. doi: 10.1097/01.GME.0000086467.82759.DA. [DOI] [PubMed] [Google Scholar]
  • 44.Agencia Española de Medicamentos y Productos Sanitarios. Restricciones terapéuticas de la terapia hormonal sustitutiva en la menopausia. Nota informativa 2004/01, febrero de 2004.
  • 44.Kannel W.B. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol. 1988;62:1109–1112. doi: 10.1016/0002-9149(88)90558-9. [DOI] [PubMed] [Google Scholar]
  • 45.The pooling project research group Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. J Chronic Dis. 1978;31:201–306. doi: 10.1016/0021-9681(78)90073-5. [DOI] [PubMed] [Google Scholar]
  • 46.Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet. 1998;351:1425–1427. doi: 10.1016/S0140-6736(97)11321-6. [DOI] [PubMed] [Google Scholar]
  • 47.Willett W.C., Walter C., Coldizt G.A., Stampfer M. Postmenopausal estrogens opposed, unopposed or none of the above. JAMA. 2000;283:534–535. doi: 10.1001/jama.283.4.534. [DOI] [PubMed] [Google Scholar]
  • 48.Grodstein F., Clarckson T.B., Manson J.A. Understanding the divergent data on postmenopausal hormone therapy. N Engl J M. 2003;348:645–650. doi: 10.1056/NEJMsb022365. [DOI] [PubMed] [Google Scholar]
  • 49.White C. Second long term HRT trial stopped early. BMJ. 2002;325:987. doi: 10.1136/bmj.325.7371.987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L. Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333. doi: 10.1001/jama.288.3.321. [DOI] [PubMed] [Google Scholar]
  • 51.Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–613. doi: 10.1001/jama.280.7.605. [DOI] [PubMed] [Google Scholar]
  • 52.Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., Shumaker S.A., Snyder T.E. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522–529. doi: 10.1056/NEJM200008243430801. [DOI] [PubMed] [Google Scholar]
  • 53.Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) JAMA. 2002;288:49–57. doi: 10.1001/jama.288.1.49. [DOI] [PubMed] [Google Scholar]
  • 54.Sackett D.L. La soberbia de la medicina preventiva. CMAJ. 2002;167:363–364. [PMC free article] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES